EPRX
Eupraxia Pharmaceuticals Inc. (EPRX) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (D+). The rating has held at C for 14 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.5) | D+ (1.7) | C- (1.9) | B (3.4) | C+ (2.6) | C (2.4) |
| 2026-11-04 | C+ (2.5) | D+ (1.7) | C- (1.9) | B (3.4) | C+ (2.7) | C (2.4) |
| 2026-10-28 | C+ (2.5) | D+ (1.7) | C- (2.0) | B+ (3.6) | C+ (2.7) | C (2.5) |
| 2026-10-21 | C+ (2.5) | D+ (1.6) | C- (2.0) | B+ (3.6) | C+ (2.6) | C (2.5) |
| 2026-10-14 | C+ (2.5) | D+ (1.6) | C- (2.0) | B (3.2) | C+ (2.6) | C (2.4) |